Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
EP: 1.A High-Risk Myeloma Patient’s Path to CAR T: Personal and Clinical Perspectives
EP: 2.Behind the Scenes: Patient Education and Decision-Making for CAR T
EP: 3.Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
EP: 4.The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations
EP: 5.From Collection to Infusion: Comprehensive CAR T Treatment and Management Strategies From CAR T Specialists
EP: 6.The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
Now Viewing
EP: 7.Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Video content above is prompted by the following:
- How has your life changed since receiving CAR T therapy? How has CAR T therapy impacted your overall quality of life compared with your previous treatments? Based on your experience, what advice would you give to other patients with multiple myeloma who are considering CAR T therapy?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
